Form 8-K Kymera Therapeutics, For: May 09
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Truist Securities 'Incrementally Positive' on Kymera Therapeutics (KYMR) Following Q1 Update
May 9, 2025 1:57 PM EDTTruist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $53.00 price target on Kymera Therapeutics (NASDAQ: KYMR) following Q1 results.
The analyst commented, "We are incrementally positive on KYMR following today's 1Q25 business update showcasing KT-579, an oral, selective degrader of... More
